+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain



Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain



Journal of Infectious Diseases 172(1): 19-24



A human papillomavirus (HPV) type 16 virus-like particle-based ELISA was used to assess antivirion immune responses in 300 women participating in cervical cancer case-control studies in Colombia and Spain. Virion IgG antibodies were detected in the sera of 51% and 59% of women with HPV-16 DNA-positive invasive cervical cancer and 81% and 73% of women with HPV-16 DNA-positive cervical intraepithelial neoplasia grade III (CIN III) in Colombia and Spain, respectively. Capsid antibodies were detected in 22% and 3% of cancer controls (P < .001) and in 43% and 10% of CIN III controls (P = .010) from Colombia and Spain, respectively. Since Colombia has an 8-fold higher incidence of cervical cancer, these results demonstrate an association between ELISA positivity and cancer risk. Capsid antibody responses did not correlate with humoral responses of the same women to HPV-16 E6 and E7 oncoproteins.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 044301529

Download citation: RISBibTeXText

PMID: 7797910

DOI: 10.1093/infdis/172.1.19


Related references

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. International Journal of Gynecological Cancer 23(1): 148-156, 2013

Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. International Journal of Cancer 132(4): 854-867, 2013

Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Japanese Journal of Clinical Oncology 44(10): 910-917, 2014

Single type infection of human papillomavirus as a cause for high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Research 6: 46-51, 2018

Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiology, Biomarkers and Prevention 2(5): 415-422, 1993

Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia. International Journal of Gynecological Cancer 16(3): 1032-1035, 2006

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Human Immunology 66(7): 762-772, 2005

Human papillomavirus type distribution in cervical intraepithelial neoplasia grade 2/3 and cervical cancer in Portugal: a CLEOPATRE II Study. International Journal of Gynecological Cancer 23(3): 500-506, 2013

Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. Journal of Medical Virology 60(4): 403-410, 2000

No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. American Journal of Obstetrics & Gynecology 189(1): 118-120, 2003

Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. American Journal of Obstetrics & Gynecology 186(1): 28-34, 2002

Epstein-Barr virus (EBV) genes expression in cervical intraepithelial neoplasia and invasive cervical cancer: a comparative study with human papillomavirus (HPV) infection. Human Pathology 31(3): 318-326, 2000

Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. American Journal of Clinical Pathology 122(6): 902-911, 2004

Activation of the Erk/Map Kinase Pathway in Cervical Intraepithelial Neoplasia Is Related to Grade of the Lesion but not to High-Risk Human Papillomavirus, Virus Clearance, or Prognosis in Cervical Cancer. American Journal of Clinical Pathology 122(6): 902-911, 2004

T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clinical and Vaccine Immunology 17(9): 1315-1321, 2010